JP MORGAN/PUT/VERTEX PHARMACEUTICALS/315/0.1/17.01.25

JP MORGAN/PUT/VERTEX PHARMACEUTICALS/315/0.1/17.01.25 Share Price

DE000JL07U05

Market Closed - Börse Stuttgart 12:13:59 28/06/2024 pm IST
0.25 ^EUR	0.00%

Current month	-48.98%
1 month	-30.56%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/PUT/VERTEX PHARMACEUTICALS/315/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Verve Therapeutics, Inc. Announces Board Appointments	28/06	CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	27/06	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	25/06	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	24/06	MT

More news

Quotes 5-day view

Date	Price	Change
28/24/28	0.25	0.00%
27/24/27	0.25	-7.41%
26/24/26	0.27	+3.85%
25/24/25	0.26	-13.33%
24/24/24	0.3	+3.45%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 12:13 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JL07U0
ISIN	DE000JL07U05
Date issued	12/04/2023
Strike	315 $
Maturity	17/01/2025 (203 Days)
Parity	10 : 1
Emission price	3.85 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	4.55 €
Lowest since issue	0.23 €
Delta	-0.07x
Omega	6.038
Premium	33.96x
Gearing	85.82x
Moneyness	0.6720
Difference Strike	-153.7 $
Difference Strike %	-48.80%
Spread	0.5 €
Spread %	65.79%
Theoretical value	0.5100
Implied Volatility	43.83 %
Total Loss Probability	87.42 %
Intrinsic value	0.000000
Present value	0.5100
Break even	309.54 €
Theta	-0.03x
Vega	0.04x
Rho	-0.02x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

468.7 USD

Average target price

468.3 USD

Spread / Average Target

-0.10%

Consensus